Research programme: glucagon-like peptide 1 mimetics - Alizyme

Drug Profile

Research programme: glucagon-like peptide 1 mimetics - Alizyme

Alternative Names: AZM 134; Research programme AZM 134 - Alizyme

Latest Information Update: 06 May 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alizyme; Imperial College of Science, Technology and Medicine
  • Class Small molecules
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 06 May 2002 Discontinued - Preclinical for Type-2 diabetes mellitus in United Kingdom (unspecified route)
  • 01 Mar 2000 Preclinical development for Type-2 diabetes mellitus in United Kingdom (Unknown route)
  • 04 Jun 1997 Preclinical development for Type-2 diabetes mellitus in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top